NCT05764720

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

RecruitingNAINTERVENTIONAL

Trial Details

Start: 2023-05-14Est. Completion: 2028-03

Enrollment target: 134 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
Washington University, St. Louis, St Louis, Missouri, United States
UH Cleveland Medical Center, Cleveland, Ohio, United States

Contact

Kate Campbellkate.campbell@varian.com 206-218-8173

Other microbiome trials you might be interested in

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine TumoursPhase 2Recruiting

Neuroendocrine Tumors

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neu…

Sydney, AustraliaEst. completion Sep 2027

View Trial →

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerPhase 1Recruiting

Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine CarcinomaMetastatic Pancreatic AdenocarcinomaStage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.